Evolving Oral SERD Research Seeks to Redefine Treatment Strategies in Hormone Receptor+ Breast Cancer

Evolving Oral SERDs for Hormone Receptor–Positive Breast CancerOral SERDs represent a shift in the management of metastatic breast cancer because they can degrade the estrogen receptor and overcome treatment resistance caused by ESR1 mutations.Although the SERENA-6 trial demonstrated a PFS benefit when switching to an oral SERD at the first sign of molecular progression, experts and the FDA remain divided on whether to change therapy before radiographic evidence of disease appears.The adoption of oral SERDs into individual patient treatment plans is heavily influenced by patient preference for oral medication over intramuscular injections like fulvestrant, which can cause discomfort and affect overall QOL.